Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs

Journal of Clinical Microbiology

Volumn 51, Issue 2, 2013, Pages 393-401

  Horne, David J ^a   Pinto, Lancelot M ^b   Arentz, Matthew ^a   Grace Lin, S Y ^c   Desmond, Edward ^c   Flores, Laura L ^d   Steingart, Karen R ^a   Minion, Jessica ^e  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e REGINA QU APPELLE HEALTH REGION   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

ANTITUBERCULAR AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 84873030084     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02724-12     Document Type: Review

References (30)

1. Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, Raviglione M. 2012. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007-2010. Bull. World Health Organ. 90:111-119D.
2. World Health Organization. 2011. Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2011/ 9789241501583-eng.pdf Accessed 25 February 2012.
3. World Health Organization. 2011. Global tuberculosis control: WHO report 2011. WHO/HTM/TB/2010.7. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/global-report/2011/gtbr11-full.pdf Accessed 25 February 2012.
4. World Health Organization. 2008. World Health Organization Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. WHO/HTM/TB/2008.392. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/hq/2008/WHO-HTM-TB-2008.392-eng.pdf Accessed 25 February 2012.
5. Kim, SJ. 2005. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur. Respir. J. 25:564 -569.
6. Kim SJ, Espinal MA, Abe C, Bai GH, Boulahbal F, Fattorin L, Gilpin C, Hoffner S, Kam KM, Martin-Casabona N, Rigouts L, Vincent V. 2004. Is second-line anti-tuberculosis drug susceptibility testing reliable? Int. J. Tuberc. Lung Dis. 8:1157-1158.
7. Bwanga F, Hoffner S, Haile M, Joloba ML. 2009. Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect. Dis. 9:67. doi:10.1186/1471-2334-9-67.
8. Chang KC, Yew WW, Chan RC. 2010. Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and metaanalysis. J. Antimicrob. Chemother. 65:1551-1561.
9. Chang KC, Yew WW, Zhang Y. 2009. A systematic review of rapid drug susceptibility tests for multidrug-resistant tuberculosis using rifampin resistance as a surrogate. Expert Opin. Med. Diagn. 3:99 -122.
10. Ling DI, Zwerling AA, Pai M. 2008. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur. Respir. J. 32:1165-1174.
11. Martin A, Panaiotov S, Portaels F, Hoffner S, Palomino JC, Angeby K. 2008. The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J. Antimicrob. Chemother. 62:56-64.
12. Martin A, Portaels F, Palomino JC. 2007. Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J. Antimicrob. Chemother. 59:175-183.
13. Minion J, Leung E, Menzies D, Pai M. 2010. Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis. 10:688-698.
14. Morgan M, Kalantri S, Flores L, Pai M. 2005. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systemic review and meta-analysis. BMC Infect. Dis. 5:62. doi:10.1186/1471-2334-5-62.
15. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM. 2008. Systematic reviews of diagnostic test accuracy. Ann. Intern. Med. 149:889-897.
16. Macaskill P, Gatsonis C, Deeks JJ, Harbord RM, Takwoingi Y. 2010. Chapter 10: analysing and presenting results. In Deeks JJ, Bossuyt PM, Gatsonis C (ed), Cochrane handbook for systematic reviews of diagnostic test accuracy, version 090. The Cochrane Collaboration, Birmingham, England. http://srdta.cochrane.org/ Accessed 6 March 2011.
17. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM. 2011. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 155:529 -536.
18. StataCorp. 2009. Stata Statistical Software: release 11. StataCorp, College Station, TX.
19. Zamora J, Abraira V, Muriel A, Khan KS, Coomarasamy A. 2006. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med. Res. Methodol. 6:31. doi:10.1186/1471-2288-6-31.
20. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. 2005. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J. Clin. Epidemiol. 58:982-990.
21. Giampaglia CM, Martins MC, Vieira GB, Vinhas SA, Telles MA, Palaci M, Marsico AG, Hadad DJ, Mello FC, Fonseca Lde S, Kritski A. 2007. Multicentre evaluation of an automated BACTEC 960 system for susceptibility testing of Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 11:986 -991.
22. Laszlo A, Helbecque DM, Tostowaryk W. 1987. Proficiency testing of conventional drug susceptibility tests of Mycobacterium tuberculosis. Can. J. Microbiol. 33:1064 -1068.
23. Leonard B, Coronel J, Siedner M, Grandjean L, Caviedes L, Navarro P, Gilman RH, Moore DA. 2008. Inter- and intra-assay reproducibility of microplate Alamar blue assay results for isoniazid, rifampicin, ethambutol, streptomycin, ciprofloxacin, and capreomycin drug susceptibility testing of Mycobacterium tuberculosis. J. Clin. Microbiol. 46:3526 -3529.
24. Lin SY, Desmond E, Bonato D, Gross W, Siddiqi S. 2009. Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex. J. Clin. Microbiol. 47: 3630-3634.
25. Rüsch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. 2006. Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second- line drugs and newer antimicrobials. J. Clin. Microbiol. 44:688-692.
26. Angra PK, Taylor TH, Iademarco MF, Metchock B, Astles JR, Ridderhof JC. 2012. Performance of tuberculosis drug susceptibility testing in U.S. laboratories from 1994 to 2008. J. Clin. Microbiol. 50: 1233-1239.
27. Kent PT, Kubica GP. 1985. Public health mycobacteriology: a guide for the level III laboratory. U.S. Department of Health and Human Services, Atlanta, GA.
28. Van Deun A, Barrera L, Bastian I, Fattorini L, Hoffmann H, Kam KM, Rigouts L, Rusch-Gerdes S, Wright A. 2009. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J. Clin. Microbiol. 47:3501-3506.
29. Williamson DA, Roberts SA, Bower JE, Vaughan R, Newton S, Lowe O, Lewis CA, Freeman JT. 2012. Clinical failures associated with rpoB mutations in phenotypically occult multidrug-resistant Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis. 16:216 -220.
30. Tatsioni A, Zarin DA, Aronson N, Samson DJ, Flamm CR, Schmid C, Lau J. 2005. Challenges in systematic reviews of diagnostic technologies. Ann. Intern. Med. 142(12 Pt 2):1048 -1055.